Orchid Pharma Intrinsic Value

ORCHPHARMA • Healthcare

Orchid Pharma (ORCHPHARMA) median intrinsic value is ₹320.00 from 4 valuation models (range ₹219–₹497), vs current price ₹546.60 — -41.5% downside (Trading Above Calculated Value), margin of safety -70.8%. For current market price and key ratios, visit ORCHPHARMA share price.

Current Stock Price
₹546.60
Primary Intrinsic Value
₹496.86
Market Cap
₹2788 Cr
-41.5% Downside
Median Value
₹320.00
Value Range
₹219 - ₹497
Assessment
Trading Above Calculated Value
Safety Margin
-70.8%

ORCHPHARMA Valuation Methods Summary — DCF, Graham Number & P/E

Orchid Pharma intrinsic value across 4 models vs current price ₹546.60 — upside/downside and value range per method. Browse ORCHPHARMA financial statements for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
Book Value Method asset ₹496.86 ₹447.17 - ₹546.55 -9.1% Book Value/Share: ₹248.43, P/B: 2.0x
Revenue Multiple Method revenue ₹320.00 ₹288.00 - ₹352.00 -41.5% Revenue/Share: ₹160.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹218.64 ₹196.78 - ₹240.50 -60.0% EBITDA: ₹36.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹218.64 ₹174.91 - ₹262.37 -60.0% CF Growth: 5.0%, Discount: 15%
Method Types: Earnings Asset DCF Growth Dividend Conservative

ORCHPHARMA Intrinsic Value vs Market Price — All Valuation Models

Orchid Pharma fair value range ₹219–₹497 vs current market price ₹546.60 across 4 valuation models. Compare with ORCHPHARMA intrinsic value calculation to assess whether the stock is under or overvalued.

ORCHPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?

Orchid Pharma median intrinsic value ₹320.00, current price ₹546.60 — Trading Above Calculated Value by 41.5%, margin of safety -70.8%.

What is the intrinsic value of ORCHPHARMA?

Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Orchid Pharma (ORCHPHARMA) is ₹320.00 (median value). With the current market price of ₹546.60, this represents a -41.5% variance from our estimated fair value.

The valuation range spans from ₹218.64 to ₹496.86, indicating ₹218.64 - ₹496.86.

Is ORCHPHARMA undervalued or overvalued?

Based on our multi-method analysis, Orchid Pharma (ORCHPHARMA) appears to be trading above calculated value by approximately 41.5%.

ORCHPHARMA Financial Health — Key Ratios vs Industry Benchmarks

Orchid Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 5.98 Industry Standard: 2.0+ Above 2.0 Measures short-term liquidity capacity
Return on Equity -1.9% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin -1.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level
Asset Turnover Ratio 0.48x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

ORCHPHARMA Cash Flow Quality — Operating & Free Cash Flow

Orchid Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹19 Cr ₹6 Cr Positive Free Cash Flow 7/10
March 2024 ₹126 Cr ₹-30 Cr Positive Operating Cash Flow 6/10
March 2023 ₹18 Cr ₹3 Cr Positive Free Cash Flow 7/10
March 2022 ₹93 Cr ₹93 Cr Positive Free Cash Flow 8/10
March 2021 ₹24 Cr ₹24 Cr Positive Free Cash Flow 8/10